$25.55+0.12 (+0.47%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Collegium Pharmaceutical (COLL) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~29.6%/yr (FY21→FY25), net margin 8.1%, and free cash flow (~$327.6M) tracks net income. Earnings are cash, not paper.
The four lines that matter · FY21–FY25
Revenue ($M)▲23.6%
780.6
FY21→FY25CAGR +29.6%/yr
Net income ($M)▼9.1%
62.9
one-off year: see footnoteCAGR −3.2%/yr
Free cash flow ($M)▲61.1%
327.6
FY21→FY25CAGR +34.0%/yr
Diluted EPS▼7.0%
1.73
buyback-liftedCAGR −1.8%/yr
What the receipts whisper · what a headline number hides
Share count
−3.3%
41.0mn → 39.7mn diluted shares since FY21. Part of EPS growth is the shrinking denominator. Watch net income too.
Capex
$1.7M
steady at 0.2% of revenue (+5.3% YoY).
Returns vs FCF
8%
$25.1M returned vs $327.6M of FCF in FY25. Buybacks covered by cash flow.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
8¢ of every revenue dollar becomes profit. The biggest cost lever is COGS.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 54.4% → 59.3%. Net margin 8.1% is more than double the sector median.
The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 815.2 | 780.6 | 631.4 | 566.8 | 463.9 | 276.9 | ▲23.6% | +29.6% |
Cost of revenue | 333.9 | 317.3 | 254.1 | 240.6 | 254.4 | 126.3 | ▲24.9% | +25.9% |
Gross profit | 481.3 | 463.3 | 377.3 | 326.2 | 209.5 | 150.6 | ▲22.8% | +32.4% |
Research & development | — | — | — | — | 4.0 | 9.5 | — | — |
Selling, general & admin | 360.2 | 284.8 | 210.4 | 159.2 | 172.2 | 119.0 | ▲35.4% | +24.4% |
Total operating expenses | 357.3 | 283.6 | 207.4 | 159.2 | 176.2 | 133.0 | ▲36.7% | +20.8% |
Operating incomefeeds ROC rank | 124.1 | 179.6 | 169.9 | 167.0 | 33.3 | 17.6 | ▲5.7% | +78.7% |
Other income, net | −81.9 | −87.0 | −71.3 | −91.2 | −62.2 | −21.0 | — | — |
Pretax income | 42.1 | 92.6 | 98.6 | 75.7 | −28.8 | −3.4 | ▼6.0% | — |
Income tax | 4.0 | 29.7 | 29.4 | 27.6 | −3.8 | −74.9 | ▲1.3% | — |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | 38.2 | 62.9 | 69.2 | 48.2 | −25.0 | 71.5 | ▼9.1% | −3.2% |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 1.02 | 1.73 | 1.86 | 1.29 | −0.74 | 1.86 | ▼7.0% | −1.8% |
Diluted shares (mn) | 39.11 | 39.70 | 40.42 | 41.79 | 33.83 | 41.05 | ▼1.8% | −0.8% |
| Margins | ||||||||
Gross margin40th pct in Healthcare | 59.0% | 59.3% | 59.8% | 57.5% | 45.2% | 54.4% | ▼0.4pp | +4.9pp |
Operating margin | 15.2% | 23.0% | 26.9% | 29.5% | 7.2% | 6.4% | ▼3.9pp | +16.6pp |
Net margin55th pct in Healthcare | 4.7% | 8.1% | 11.0% | 8.5% | −5.4% | 25.8% | ▼2.9pp | −17.8pp |
† TTM = trailing four quarters through 2026-09-30.FY21 effective tax rate was 2220% vs a 32% norm for this window, likely a one-time item; see the filing.FY22 effective tax rate was 13% vs a 32% norm for this window, likely a one-time item; see the filing.
5 more years of statements and CSV export are on Premium, and 8 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Collegium Pharmaceutical's revenue last fiscal year?
Collegium Pharmaceutical reported revenue of $780.6M in fiscal 2025, up 23.6% from fiscal 2024.
What was Collegium Pharmaceutical's net income?
Collegium Pharmaceutical reported net income of $62.9M in fiscal 2025, a net margin of 8.1%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

